SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $123,930.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 17,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the sale, the insider owned 590,887 shares of the company’s stock, valued at approximately $4,307,566.23. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total value of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total value of $38,221.81.

SOPHiA GENETICS Stock Performance

SOPH stock traded up $1.02 during midday trading on Friday, hitting $7.71. The company’s stock had a trading volume of 963,487 shares, compared to its average volume of 220,563. The stock has a market cap of $646.79 million, a price-to-earnings ratio of -6.70 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The stock’s 50-day moving average price is $5.57 and its 200 day moving average price is $5.13. SOPHiA GENETICS SA has a 1 year low of $2.96 and a 1 year high of $7.86.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities analysts forecast that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in SOPH. Silverberg Bernstein Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after acquiring an additional 4,155 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares during the period. Principal Financial Group Inc. raised its stake in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. purchased a new stake in SOPHiA GENETICS during the 1st quarter worth about $50,000. Finally, Squarepoint Ops LLC bought a new position in SOPHiA GENETICS in the 3rd quarter worth about $49,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

Analyst Upgrades and Downgrades

Several analysts have commented on SOPH shares. HC Wainwright lifted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.